Nanexa

Nanexa AB is a Swedish pharmaceutical development company built around its proprietary PharmaShell drug-delivery platform for long-acting injectable medicines. The company develops its own product candidates and also pursues licensing and collaboration opportunities with other pharmaceutical companies.

— Nanexa
%
PharmaShell technology licensing60% Licenses and evaluation agreements for Nanexa's proprietary drug-delivery platform.
Proprietary product development40% Internal development of long-acting product candidates based on PharmaShell.

Nanexa sells primarily to pharmaceutical companies that want to develop long-acting formulations or license the...

  • Global pharmaceutical companiesprimary

    They license PharmaShell or collaborate on specific drug candidates to create long-acting products.

  • Evaluation partnersprimary

    They test whether PharmaShell can meet release, stability, and development requirements for a molecule.

  • Therapeutic-area development partnerssecondary

    They focus on obesity, type 2 diabetes, oncology, and other high-value indications.

  • Future commercialization partnerssecondary

    They may take over late-stage development and market launch of selected programs.

Nanexa is headquartered in Sweden and operates as a Swedish listed development company, with business activity centered...

  • •Headquartered and listed in Sweden
  • •Commercial partnerships are international in scope
  • •Business depends on global pharmaceutical counterparties
  • •R&D and partnering activity is not tied to one domestic market
  • •International conferences and meetings support collaboration

Nanexa's strategy is to build a portfolio of three to four proprietary product projects while also expanding...

01
Advance proprietary product projectsmedium-term

Owning product programs can create higher long-term value than platform licensing alone.

02
Expand PharmaShell licensing and collaborationsshort-term

Partnering can broaden platform use and generate licensing revenue earlier in the cycle.

03
Focus on high-value therapeutic areasmedium-term

Obesity, type 2 diabetes, and oncology offer large markets for long-acting medicines.

Nanexa faces the typical risks of drug-delivery and early-stage pharmaceutical development, including technical...

high

Competition from better-funded drug-delivery developers

Larger rivals can spend more on development, marketing, and pricing, which can weaken Nanexa's position.

Scope
PharmaShell platform and long-acting injectable market
Materiality
high
high

Product liability and clinical side effects

Adverse events in studies can delay, halt, or damage commercialization efforts.

Scope
Clinical studies and product candidates
Materiality
high
high

Regulatory scrutiny of material safety

Authorities may require additional studies if they see potential risks in the PharmaShell material.

Scope
Approval pathway
Materiality
high
high

Dependence on partners and licensing deals

Many evaluation projects may not progress into product projects or signed licenses.

Scope
Outlicensing and collaborations
Materiality
high
medium

Technology not suitable for all drugs

PharmaShell may not achieve the required release profile across every molecule or formulation.

Scope
Platform applicability
Materiality
high
Capitalized development expenditure
Can materially affect assets and impairment charges
Revenue from services and collaborations
Affects reported revenue timing and comparability
Impairment testing of non-financial assets
Can create volatile charges in development-stage companies
Foreign currency translation
Can affect receivables, liabilities, and reported results

Nano Nuclear Energy Inc.

NNE · Electric Services

CNBX Pharmaceuticals Inc.

CNBX · Pharmaceutical Preparations

ANAVEX LIFE SCIENCES CORP.

AVXL · Biological Products, (No Diagnostic Substances)

Annexon, Inc.

ANNX · Pharmaceutical Preparations

Natera, Inc.

NTRA · Services-Medical Laboratories

NEXT-ChemX Corporation.

Miscellaneous Chemical Products

: 11/08/2026